An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.
Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, Akatani N, Yamase T, Kunita Y, Watanabe S, Hiromasa T, Mori H, Hirata K, Watanabe S, Higuchi T, Tomonaga H, Kinuya S.
Inaki A, et al. Among authors: kayano d.
Ann Nucl Med. 2022 Mar;36(3):267-278. doi: 10.1007/s12149-021-01699-0. Epub 2021 Dec 6.
Ann Nucl Med. 2022.
PMID: 34870794
Free PMC article.
Clinical Trial.